Treating Hypopituitarism in the Over 65s: Review of Clinical Studies

References

• Higham CE, Johannsson G, Shalet SM. Hypopituitarism. Lancet. 2016;388(10058):2403–2415. doi:10.1016/S0140-6736(16)30053-8
   PubMed Web of Science ®Google Scholar
• Pekic S, Popovic V. DIAGNOSIS OF ENDOCRINE DISEASE: expanding the cause of hypopituitarism. Eur J Endocrinol. 2017;176(6):R269–R282.
   PubMed Web of Science ®Google Scholar
• Pappachan JM, Raskauskiene D, Kutty VR, Clayton RN. Excess mortality associated with hypopituitarism in adults: a meta-analysis of observational studies. J Clin Endocrinol Metab. 2015;100(4):1405–1411.
   PubMed Web of Science ®Google Scholar
• Spina A, Losa M, Mortini P. Pituitary adenomas in elderly patients: clinical and surgical outcome analysis in a large series. Endocrine. 2019;65(3):637–645.
   PubMed Web of Science ®Google Scholar
• Foppiani L, Ruelle A, Bandelloni R, Quilici P, Del monte P. Hypopituitarism in the elderly: multifaceted clinical and biochemical presentation. Curr Aging Sci. 2008;1(1):42–50.
   PubMedGoogle Scholar
• Singh S, Bajorek B. Defining ‘elderly’ in clinical practice guidelines for pharmacotherapy. Pharm Pract (Granada). 2014;12(4):489.
   PubMedGoogle Scholar
• Dekkers OM, Pereira AM, Roelfsema F, et al. Observation alone after transsphenoidal surgery for nonfunctioning pituitary macroadenoma. J Clin Endocrinol Metab. 2006;91(5):1796–1801.
   PubMed Web of Science ®Google Scholar
• Villar-Taibo R, Diaz-Ortega C, Sifontes-Dubon M, et al. Pituitary surgery in elderly patients: a safe and effective procedure. Endocrine. 2021;72(3):814–822.
   PubMed Web of Science ®Google Scholar
• Minniti G, Esposito V, Piccirilli M, Fratticci A, Santoro A, Jaffrain-Rea ML. Diagnosis and management of pituitary tumours in the elderly: a review based on personal experience and evidence of literature. Eur J Endocrinol. 2005;153(6):723–735.
   PubMed Web of Science ®Google Scholar
• Dekkers OM, Pereira AM, Romijn JA. Treatment and follow-up of clinically nonfunctioning pituitary macroadenomas. J Clin Endocrinol Metab. 2008;93(10):3717–3726.
   PubMed Web of Science ®Google Scholar
• Hage C, Salvatori R. Speed of response to dopaminergic agents in prolactinomas. Endocrine. 2022;75(3):883–888.
   PubMed Web of Science ®Google Scholar
• Carosi G, Brunetti A, Mangone A, et al. A Multicenter Cohort Study in Patients With Primary Empty Sella: hormonal and Neuroradiological Features Over a Long Follow-Up. Front Endocrinol (Lausanne). 2022;13:925378.
   PubMed Web of Science ®Google Scholar
• De Marinis L, Bonadonna S, Bianchi A, Maira G, Giustina A. Primary empty sella. J Clin Endocrinol Metab. 2005;90(9):5471–5477.
   PubMed Web of Science ®Google Scholar
• Antonopoulou M, Sharma R, Farag A, Banerji MA, Karam JG. Hypopituitarism in the elderly. Maturitas. 2012;72(4):277–285.
   PubMed Web of Science ®Google Scholar
• Torino F, Corsello SM, Salvatori R. Endocrinological side-effects of immune checkpoint inhibitors. Curr Opin Oncol. 2016;28(4):278–287.
   PubMed Web of Science ®Google Scholar
• Faje AT, Sullivan R, Lawrence D, et al. Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma. J Clin Endocrinol Metab. 2014;99(11):4078–4085.
   PubMed Web of Science ®Google Scholar
• Di Dalmazi G, Ippolito S, Lupi I, Caturegli P. Hypophysitis induced by immune checkpoint inhibitors: a 10-year assessment. Expert Rev Endocrinol Metab. 2019;14(6):381–398.
   PubMed Web of Science ®Google Scholar
• Buckley TM, Schatzberg AF. On the interactions of the hypothalamic-pituitary-adrenal (HPA) axis and sleep: normal HPA axis activity and circadian rhythm, exemplary sleep disorders. J Clin Endocrinol Metab. 2005;90(5):3106–3114.
   PubMed Web of Science ®Google Scholar
• Caputo M, Mele C, Ferrero A, et al. Dynamic Tests in Pituitary Endocrinology: pitfalls in Interpretation during Aging. Neuroendocrinology. 2022;112(1):1–14.
   PubMed Web of Science ®Google Scholar
• Packard AE, Egan AE, Ulrich-Lai YM, Axis HPA. Interactions with Behavioral Systems. Compr Physiol. 2016;6(4):1897–1934.
   PubMed Web of Science ®Google Scholar
• Gadelha MR, Karavitaki N, Fudin J, Bettinger JJ, Raff H, Ben-Shlomo A. Opioids and pituitary function: expert opinion. Pituitary. 2022;25(1):52–63.
   PubMed Web of Science ®Google Scholar
• Tunbridge WM, Evered DC, Hall R, et al. The spectrum of thyroid disease in a community: the Whickham survey. Clin Endocrinol (Oxf). 1977;7(6):481–493.
   PubMed Web of Science ®Google Scholar
• van Coevorden A, Laurent E, Decoster C, et al. Decreased basal and stimulated thyrotropin secretion in healthy elderly men. J Clin Endocrinol Metab. 1989;69(1):177–185.
   PubMed Web of Science ®Google Scholar
• Bremner AP, Feddema P, Leedman PJ, et al. Age-related changes in thyroid function: a longitudinal study of a community-based cohort. J Clin Endocrinol Metab. 2012;97(5):1554–1562.
   PubMed Web of Science ®Google Scholar
• Fliers E, Boelen A. An update on non-thyroidal illness syndrome. J Endocrinol Invest. 2021;44(8):1597–1607.
   PubMed Web of Science ®Google Scholar
• Wajner SM, Maia AL. New Insights toward the Acute Non-Thyroidal Illness Syndrome. Front Endocrinol (Lausanne). 2012;3:8.
   PubMedGoogle Scholar
• Tenover JS, McLachlan RI, Dahl KD, Burger HG, de Kretser DM, Bremner WJ. Decreased serum inhibin levels in normal elderly men: evidence for a decline in Sertoli cell function with aging. J Clin Endocrinol Metab. 1988;67(3):455–459.
   PubMed Web of Science ®Google Scholar
• Tenover JS, Matsumoto AM, Plymate SR, Bremner WJ. The effects of aging in normal men on bioavailable testosterone and luteinizing hormone secretion: response to clomiphene citrate. J Clin Endocrinol Metab. 1987;65(6):1118–1126.
   PubMed Web of Science ®Google Scholar
• Santoro N, Randolph JF. Reproductive hormones and the menopause transition. Obstet Gynecol Clin North Am. 2011;38(3):455–466.
   PubMed Web of Science ®Google Scholar
• Clarke SA, Dhillo WS. Kisspeptin across the human lifespan: evidence from animal studies and beyond. J Endocrinol. 2016;229(3):R83–98.
   PubMed Web of Science ®Google Scholar
• Veldhuis JD. Changes in pituitary function with ageing and implications for patient care. Nat Rev Endocrinol. 2013;9(4):205–215.
   PubMed Web of Science ®Google Scholar
• Weltman A, Weltman JY, Hartman ML, et al. Relationship between age, percentage body fat, fitness, and 24-hour growth hormone release in healthy young adults: effects of gender. J Clin Endocrinol Metab. 1994;78(3):543–548.
   PubMed Web of Science ®Google Scholar
• Schilbach K, Bidlingmaier M. Laboratory investigations in the diagnosis and follow-up of GH-related disorders. Arch Endocrinol Metab. 2019;63(6):618–629.
   PubMed Web of Science ®Google Scholar
• Barzilai N, Huffman DM, Muzumdar RH, Bartke A. The critical role of metabolic pathways in aging. Diabetes. 2012;61(6):1315–1322.
   PubMed Web of Science ®Google Scholar
• Bernard V, Young J, Binart N. Prolactin - a pleiotropic factor in health and disease. Nat Rev Endocrinol. 2019;15(6):356–365.
   PubMed Web of Science ®Google Scholar
• Marras C, Beck JC, Bower JH, et al. Prevalence of Parkinson’s disease across North America. NPJ Parkinsons Dis. 2018;4:21.
   PubMed Web of Science ®Google Scholar
• Hawkins RC. Age and gender as risk factors for hyponatremia and hypernatremia. Clin Chim Acta. 2003;337(1–2):169–172.
   PubMed Web of Science ®Google Scholar
• Cowen LE, Hodak SP, Verbalis JG. Age-associated abnormalities of water homeostasis. Endocrinol Metab Clin North Am. 2013;42(2):349–370.
   PubMed Web of Science ®Google Scholar
• Phillips PA, Rolls BJ, Ledingham JG, et al. Reduced thirst after water deprivation in healthy elderly men. N Engl J Med. 1984;311(12):753–759.
   PubMed Web of Science ®Google Scholar
• Nanba K, Vaidya A, Rainey WE. Aging and Adrenal Aldosterone Production. Hypertension. 2018;71(2):218–223.
   PubMed Web of Science ®Google Scholar
• Monahan KD. Effect of aging on baroreflex function in humans. Am J Physiol Regul Integr Comp Physiol. 2007;293(1):R3–r12.
   PubMed Web of Science ®Google Scholar
• Brabant A, Brabant G, Schuermeyer T, et al. The role of glucocorticoids in the regulation of thyrotropin. Acta Endocrinol (Copenh). 1989;121(1):95–100.
   PubMedGoogle Scholar
• Mathioudakis N, Thapa S, Wand GS, Salvatori R. ACTH-secreting pituitary microadenomas are associated with a higher prevalence of central hypothyroidism compared to other microadenoma types. Clin Endocrinol (Oxf). 2012;77(6):871–876.
   PubMed Web of Science ®Google Scholar
• Haugen BR. Drugs that suppress TSH or cause central hypothyroidism. Best Pract Res Clin Endocrinol Metab. 2009;23(6):793–800.
   PubMed Web of Science ®Google Scholar
• Prete A, Bancos I. Glucocorticoid induced adrenal insufficiency. BMJ. 2021;374:n1380.
   PubMedGoogle Scholar
• Fleseriu M, Hashim IA, Karavitaki N, et al. Hormonal Replacement in Hypopituitarism in Adults: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2016;101(11):3888–3921.
   PubMed Web of Science ®Google Scholar
• Javorsky BR, Raff H, Carroll TB, et al. New Cutoffs for the Biochemical Diagnosis of Adrenal Insufficiency after ACTH Stimulation using Specific Cortisol Assays. J Endocr Soc. 2021;5(4):bvab022.
   PubMed Web of Science ®Google Scholar
• Raverot V, Richet C, Morel Y, Raverot G, Borson-Chazot F. Establishment of revised diagnostic cut-offs for adrenal laboratory investigation using the new Roche Diagnostics Elecsys((R)) Cortisol II assay. Annales d’endocrinologie. 2016;77(5):620–622.
   PubMed Web of Science ®Google Scholar
• Ishikawa SE, Schrier RW. Pathophysiological roles of arginine vasopressin and aquaporin-2 in impaired water excretion. Clin Endocrinol (Oxf). 2003;58(1):1–17.
   PubMed Web of Science ®Google Scholar
• van Staa TP, Leufkens HG, Abenhaim L, Begaud B, Zhang B, Cooper C. Use of oral corticosteroids in the United Kingdom. QJM. 2000;93(2):105–111.
   PubMed Web of Science ®Google Scholar
• Charmandari E, Nicolaides NC, Chrousos GP. Adrenal insufficiency. Lancet. 2014;383(9935):2152–2167.
   PubMed Web of Science ®Google Scholar
• Paragliola RM, Papi G, Pontecorvi A, Corsello SM. Treatment with Synthetic Glucocorticoids and the Hypothalamus-Pituitary-Adrenal Axis. Int J Mol Sci. 2017;18:10.
   PubMed Web of Science ®Google Scholar
• Ho KK, Participants GHDCW. Consensus guidelines for the diagnosis and treatment of adults with GH deficiency II: a statement of the GH Research Society in association with the European Society for Pediatric Endocrinology, Lawson Wilkins Society, European Society of Endocrinology, Japan Endocrine Society, and Endocrine Society of Australia. Eur J Endocrinol. 2007;157(6):695–700.
   PubMed Web of Science ®Google Scholar
• Garcia JM, Biller BMK, Korbonits M, et al. Sensitivity and specificity of the macimorelin test for diagnosis of AGHD. Endocrine Connections. 2021;10(1):76–83.
   PubMed Web of Science ®Google Scholar
• Christ-Crain M, Morgenthaler NG, Fenske W. Copeptin as a biomarker and a diagnostic tool in the evaluation of patients with polyuria-polydipsia and hyponatremia. Best Pract Res Clin Endocrinol Metab. 2016;30(2):235–247.
   PubMed Web of Science ®Google Scholar
• Rosa IN. de Sousa Munhoz Soares AA, Rodrigues MP, Naves LA. Classic cardiovascular risk factors improve in very elderly hypopituitary patients treated on standard hormone replacement in long term follow- up. Clin Diabetes Endocrinol. 2021;7(1):6.
   PubMedGoogle Scholar
• Oster H, Challet E, Ott V, et al. The Functional and Clinical Significance of the 24-Hour Rhythm of Circulating Glucocorticoids. Endocr Rev. 2017;38(1):3–45.
   PubMed Web of Science ®Google Scholar
• Stewart PM. Modified-Release Hydrocortisone: is It Time to Change Clinical Practice? J Endocr Soc. 2019;3(6):1150–1153.
   PubMed Web of Science ®Google Scholar
• Morgan SA, Berryman DE, List EO, Lavery GG, Stewart PM, Kopchick JJ. Regulation of 11beta-HSD1 by GH/IGF-1 in key metabolic tissues may contribute to metabolic disease in GH deficient patients. Growth Horm IGF Res. 2022;62:101440.
   PubMed Web of Science ®Google Scholar
• Hassan-Smith Z, Morgan S, Sherlock M, et al. 11β-hydroxysteroid dehydrogenase type 1 and age-associated muscle weakness in mice: implications for human ageing. Lancet. 2014;1:383.
   PubMedGoogle Scholar
• Holmes MC, Carter RN, Noble J, et al. 11beta-hydroxysteroid dehydrogenase type 1 expression is increased in the aged mouse hippocampus and parietal cortex and causes memory impairments. J Neurosci. 2010;30(20):6916–6920.
   PubMed Web of Science ®Google Scholar
• Kim BJ, Lee NR, Lee CH, et al. Increased Expression of 11beta-Hydroxysteroid Dehydrogenase Type 1 Contributes to Epidermal Permeability Barrier Dysfunction in Aged Skin. Int J Mol Sci. 2021;22:11.
   PubMed Web of Science ®Google Scholar
• Bornstein SR, Allolio B, Arlt W, et al. Diagnosis and Treatment of Primary Adrenal Insufficiency: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2016;101(2):364–389.
   PubMed Web of Science ®Google Scholar
• Chan S, Debono M. Replication of cortisol circadian rhythm: new advances in hydrocortisone replacement therapy. Ther Adv Endocrinol Metab. 2010;1(3):129–138.
   PubMedGoogle Scholar
• Gasco V, Giannelli J, Campioni L, et al. Benefits of dual-release hydrocortisone treatment on central adiposity and health-related quality of life in secondary adrenal insufficiency. J Endocrinol Invest. 2022;1:548.
   Google Scholar
• Alexandraki KI, Grossman A. Management of Hypopituitarism. J Clin Med. 2019;8:12.
   Web of Science ®Google Scholar
• Li X, Yang H, Duan Z, et al. A case series study of hypopituitarism in older patients with and without gastrointestinal symptoms. Postgrad Med. 2018;130(5):501–506.
   PubMed Web of Science ®Google Scholar
• Rushworth RL, Torpy DJ, Falhammar H. Adrenal crises in older patients. Lancet Diabetes Endocrinol. 2020;8(7):628–639.
   PubMed Web of Science ®Google Scholar
• Baker WL, Karan S, Kenny AM. Effect of dehydroepiandrosterone on muscle strength and physical function in older adults: a systematic review. J Am Geriatr Soc. 2011;59(6):997–1002.
   PubMed Web of Science ®Google Scholar
• Jankowski CM, Gozansky WS, Schwartz RS, et al. Effects of dehydroepiandrosterone replacement therapy on bone mineral density in older adults: a randomized, controlled trial. J Clin Endocrinol Metab. 2006;91(8):2986–2993.
   PubMed Web of Science ®Google Scholar
• Villareal DT, Holloszy JO. Effect of DHEA on abdominal fat and insulin action in elderly women and men: a randomized controlled trial. JAMA. 2004;292(18):2243–2248.
   PubMed Web of Science ®Google Scholar
• Meneilly GS, Cheung E, Tuokko H. Altered responses to hypoglycemia of healthy elderly people. J Clin Endocrinol Metab. 1994;78(6):1341–1348.
   PubMed Web of Science ®Google Scholar
• Harvey JC, de Klerk J. The Houssay phenomenon in man. Am J Med. 1955;19(3):327–336.
   PubMed Web of Science ®Google Scholar
• Gaffar Mohammed M, Baloch J, Alsahhar AM, Alhabashi BM. Recurrent Hypoglycemia in Diabetic Patient With Hypopituitarism: the Houssay Phenomenon. Cureus. 2021;13(2):e13422.
   PubMed Web of Science ®Google Scholar
• Zhang JTW, Ho KWK. Houssay phenomenon: a rare case of diabetes mellitus remission. European Diabetes Nursing. 2015;8(3):115–116.
   Google Scholar
• Soysal P, Babacan-Yildiz G, Isik AT. Pituitary insufficiency: a cause of hypoglycemia in an elderly diabetic patient. Geriatr Gerontol Int. 2012;12(4):752–753.
   PubMed Web of Science ®Google Scholar
• Mazziotti G, Formenti AM, Frara S, et al. MANAGEMENT OF ENDOCRINE DISEASE: risk of overtreatment in patients with adrenal insufficiency: current and emerging aspects. Eur J Endocrinol. 2017;177(5):R231–R248.
   PubMed Web of Science ®Google Scholar
• Rawla P. Epidemiology of Prostate Cancer. World J Oncol. 2019;10(2):63–89.
   PubMedGoogle Scholar
• Fizazi K, Tran N, Fein L, et al. Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer. N Engl J Med. 2017;377(4):352–360.
   PubMed Web of Science ®Google Scholar
• Auchus RJ, Yu MK, Nguyen S, Mundle SD. Use of prednisone with Abiraterone acetate in metastatic castration-resistant prostate cancer. Oncologist. 2014;19(12):1231–1240.
   PubMed Web of Science ®Google Scholar
• Smans LC, Van der Valk ES, Hermus AR, Zelissen PM. Incidence of adrenal crisis in patients with adrenal insufficiency. Clin Endocrinol (Oxf). 2016;84(1):17–22.
   PubMed Web of Science ®Google Scholar
• Sychev DA, Ashraf GM, Svistunov AA, et al. The cytochrome P450 isoenzyme and some new opportunities for the prediction of negative drug interaction in vivo. Drug Des Devel Ther. 2018;12:1147–1156.
   PubMed Web of Science ®Google Scholar
• Rushworth RL, Torpy DJ, Falhammar H. Adrenal Crisis. N Engl J Med. 2019;381(9):852–861.
   PubMed Web of Science ®Google Scholar
• Roos A, Linn-Rasker SP, van Domburg RT, Tijssen JP, Berghout A. The starting dose of levothyroxine in primary hypothyroidism treatment: a prospective, randomized, double-blind trial. Arch Intern Med. 2005;165(15):1714–1720.
   PubMed Web of Science ®Google Scholar
• Ferretti E, Persani L, Jaffrain-Rea ML, Giambona S, Tamburrano G, Beck-Peccoz P. Evaluation of the adequacy of levothyroxine replacement therapy in patients with central hypothyroidism. J Clin Endocrinol Metab. 1999;84(3):924–929.
   PubMed Web of Science ®Google Scholar
• Turner MR, Camacho X, Fischer HD, et al. Levothyroxine dose and risk of fractures in older adults: nested case-control study. BMJ. 2011;342:d2238.
   PubMedGoogle Scholar
• Effraimidis G, Watt T, Feldt-Rasmussen U. Levothyroxine Therapy in Elderly Patients With Hypothyroidism. Front Endocrinol (Lausanne). 2021;12:641560.
   Web of Science ®Google Scholar
• Klose M, Marina D, Hartoft-Nielsen ML, et al. Central hypothyroidism and its replacement have a significant influence on cardiovascular risk factors in adult hypopituitary patients. J Clin Endocrinol Metab. 2013;98(9):3802–3810.
   PubMed Web of Science ®Google Scholar
• Cappola AR, Desai AS, Medici M, et al. Thyroid and Cardiovascular Disease Research Agenda for Enhancing Knowledge, Prevention, and Treatment. Circulation. 2019;1:5665.
   PubMedGoogle Scholar
• Jasim S, Alahdab F, Ahmed AT, et al. Mortality in adults with hypopituitarism: a systematic review and meta-analysis. Endocrine. 2017;56(1):33–42.
   PubMed Web of Science ®Google Scholar
• Paragliola RM, Prete A, Kaplan PW, Corsello SM, Salvatori R. Treatment of hypopituitarism in patients receiving antiepileptic drugs. Lancet Diabetes Endocrinol. 2015;3(2):132–140.
   PubMed Web of Science ®Google Scholar
• de Carvalho GA, Paz-Filho G, Mesa Junior C, Graf H. MANAGEMENT OF ENDOCRINE DISEASE: pitfalls on the replacement therapy for primary and central hypothyroidism in adults. Eur J Endocrinol. 2018;178(6):R231–R244.
   PubMed Web of Science ®Google Scholar
• Shimon I, Cohen O, Lubetsky A, Olchovsky D. Thyrotropin suppression by thyroid hormone replacement is correlated with thyroxine level normalization in central hypothyroidism. Thyroid. 2002;12(9):823–827.
   PubMed Web of Science ®Google Scholar
• Bartalena L, Bogazzi F, Chiovato L, Hubalewska-Dydejczyk A, Links TP, Vanderpump M. 2018 European Thyroid Association (ETA) Guidelines for the Management of Amiodarone-Associated Thyroid Dysfunction. Eur Thyroid J. 2018;7(2):55–66.
   PubMed Web of Science ®Google Scholar
• Cappelli C, Pirola I, Daffini L, Gandossi E, Agosti B, Castellano M. Thyroid hormonal profile in elderly patients treated with two different levothyroxine formulations: a single institute survey. Eur Geriatr Med. 2014;5(6):382–385.
   PubMed Web of Science ®Google Scholar
• Shin YS, Park JK. The Optimal Indication for Testosterone Replacement Therapy in Late Onset Hypogonadism. J Clin Med. 2019;8:2.
   Web of Science ®Google Scholar
• Borst SE, Mulligan T. Testosterone replacement therapy for older men. Clin Interv Aging. 2007;2(4):561–566.
   Web of Science ®Google Scholar
• Snyder PJ, Bhasin S, Cunningham GR, et al. Effects of Testosterone Treatment in Older Men. N Engl J Med. 2016;374(7):611–624.
   PubMed Web of Science ®Google Scholar
• Cunningham GR, Stephens-Shields AJ, Rosen RC, et al. Testosterone Treatment and Sexual Function in Older Men With Low Testosterone Levels. J Clin Endocrinol Metab. 2016;101(8):3096–3104.
   PubMed Web of Science ®Google Scholar
• Sih R, Morley JE, Kaiser FE, Perry HM, Patrick P, Ross C. Testosterone replacement in older hypogonadal men: a 12-month randomized controlled trial. J Clin Endocrinol Metab. 1997;82(6):1661–1667.
   PubMed Web of Science ®Google Scholar
• Gregori G, Celli A, Barnouin Y, et al. Cognitive response to testosterone replacement added to intensive lifestyle intervention in older men with obesity and hypogonadism: prespecified secondary analyses of a randomized clinical trial. Am J Clin Nutr. 2021;114(5):1590–1599.
   PubMed Web of Science ®Google Scholar
• Srinivas-Shankar U, Roberts SA, Connolly MJ, et al. Effects of testosterone on muscle strength, physical function, body composition, and quality of life in intermediate-frail and frail elderly men: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab. 2010;95(2):639–650.
   PubMed Web of Science ®Google Scholar
• Storer TW, Basaria S, Traustadottir T, et al. Effects of Testosterone Supplementation for 3 Years on Muscle Performance and Physical Function in Older Men. J Clin Endocrinol Metab. 2017;102(2):583–593.
   PubMed Web of Science ®Google Scholar
• Basaria S, Coviello AD, Travison TG, et al. Adverse events associated with testosterone administration. N Engl J Med. 2010;363(2):109–122.
   PubMed Web of Science ®Google Scholar
• Amory JK, Watts NB, Easley KA, et al. Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone. J Clin Endocrinol Metab. 2004;89(2):503–510.
   PubMed Web of Science ®Google Scholar
• Page ST, Amory JK, Bowman FD, et al. Exogenous testosterone (T) alone or with finasteride increases physical performance, grip strength, and lean body mass in older men with low serum T. J Clin Endocrinol Metab. 2005;90(3):1502–1510.
   PubMed Web of Science ®Google Scholar
• Kapoor D, Goodwin E, Channer KS, Jones TH. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol. 2006;154(6):899–906.
   PubMed Web of Science ®Google Scholar
• Emmelot-Vonk MH, Verhaar HJ, Nakhai Pour HR, et al. Effect of testosterone supplementation on functional mobility, cognition, and other parameters in older men: a randomized controlled trial. JAMA. 2008;299(1):39–52.
   PubMed Web of Science ®Google Scholar
• Basu R, Dalla Man C, Campioni M, et al. Effect of 2 years of testosterone replacement on insulin secretion, insulin action, glucose effectiveness, hepatic insulin clearance, and postprandial glucose turnover in elderly men. Diabetes Care. 2007;30(8):1972–1978.
   PubMed Web of Science ®Google Scholar
• Curtò L, Trimarchi F. Hypopituitarism in the elderly: a narrative review on clinical management of hypothalamic–pituitary–gonadal, hypothalamic–pituitary–thyroid and hypothalamic–pituitary–adrenal axes dysfunction. J Endocrinol Invest. 2016;39(10):1115–1124.
   PubMed Web of Science ®Google Scholar
• Basaria S, Harman SM, Travison TG, et al. Effects of Testosterone Administration for 3 Years on Subclinical Atherosclerosis Progression in Older Men With Low or Low-Normal Testosterone Levels: a Randomized Clinical Trial. JAMA. 2015;314(6):570–581.
   PubMed Web of Science ®Google Scholar
• Yabluchanskiy A, Tsitouras PD. Is Testosterone Replacement Therapy in Older Men Effective and Safe? Drugs Aging. 2019;36(11):981–989.
   PubMed Web of Science ®Google Scholar
• Walker RF, Zakai NA, MacLehose RF, et al. Association of Testosterone Therapy With Risk of Venous Thromboembolism Among Men With and Without Hypogonadism. JAMA Intern Med. 2020;180(2):190–197.
   PubMed Web of Science ®Google Scholar
• Fernández-Balsells MM, Murad MH, Lane M, et al. Clinical review 1: adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2010;95(6):2560–2575.
   PubMed Web of Science ®Google Scholar
• Calof OM, Singh AB, Lee ML, et al. Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials. J Gerontol a Biol Sci Med Sci. 2005;60(11):1451–1457.
   PubMed Web of Science ®Google Scholar
• Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2010;95(6):2536–2559.
   PubMed Web of Science ®Google Scholar
• Bhasin S, Lincoff AM, Basaria S, et al. Effects of long-term testosterone treatment on cardiovascular outcomes in men with hypogonadism: rationale and design of the TRAVERSE study. Am Heart J. 2022;245:41–50.
   PubMed Web of Science ®Google Scholar
• Lee SY, Tung HH, Liu CY, Chen LK. Physical Activity and Sarcopenia in the Geriatric Population: a Systematic Review. J Am Med Dir Assoc. 2018;19(5):378–383.
   PubMed Web of Science ®Google Scholar
• Aguiar-Oliveira MH, Salvatori R. Disruption of the GHRH receptor and its impact on children and adults: the Itabaianinha syndrome. Rev Endocr Metab Disord. 2021;22(1):81–89.
   PubMed Web of Science ®Google Scholar
• Twickler TB, Cramer MJ, Dallinga-Thie GM, Chapman MJ, Erkelens DW, Koppeschaar HP. Adult-onset growth hormone deficiency: relation of postprandial dyslipidemia to premature atherosclerosis. J Clin Endocrinol Metab. 2003;88(6):2479–2488.
   PubMed Web of Science ®Google Scholar
• Castillo AR, Zantut-Wittmann DE, Neto AM, Jales RM, Garmes HM. Panhypopituitarism Without GH Replacement: about Insulin Sensitivity, CRP Levels, and Metabolic Syndrome. Horm Metab Res. 2018;50(9):690–695.
   PubMed Web of Science ®Google Scholar
• Scarano E, Riccio E, Somma T, et al. Impact of Long-Term Growth Hormone Replacement Therapy on Metabolic and Cardiovascular Parameters in Adult Growth Hormone Deficiency: comparison Between Adult and Elderly Patients. Front Endocrinol (Lausanne). 2021;12:635983.
   PubMed Web of Science ®Google Scholar
• Toogood A, O’Neill P, Shalet S. Beyond the somatopause: growth hormone deficiency in adults over the age of 60 years. J Clin Endocrinol Metab. 1996;81:460–465.
   PubMed Web of Science ®Google Scholar
• Kokshoorn NE, Biermasz NR, Roelfsema F, Smit JW, Pereira AM, Romijn JA. GH replacement therapy in elderly GH-deficient patients: a systematic review. Eur J Endocrinol. 2011;164(5):657–665.
   PubMed Web of Science ®Google Scholar
• Franco C, Johannsson G, Bengtsson BA, Svensson J. Baseline characteristics and effects of growth hormone therapy over two years in younger and elderly adults with adult onset GH deficiency. J Clin Endocrinol Metab. 2006;91(11):4408–4414.
   PubMed Web of Science ®Google Scholar
• Sathiavageeswaran M, Burman P, Lawrence D, et al. Effects of GH on cognitive function in elderly patients with adult-onset GH deficiency: a placebo-controlled 12-month study. Eur J Endocrinol. 2007;156(4):439–447.
   PubMed Web of Science ®Google Scholar
• Elbornsson M, Gotherstrom G, Franco C, Bengtsson BA, Johannsson G, Svensson J. Effects of 3-year GH replacement therapy on bone mineral density in younger and elderly adults with adult-onset GH deficiency. Eur J Endocrinol. 2012;166(2):181–189.
   PubMed Web of Science ®Google Scholar
• Monson JP, Abs R, Bengtsson BA, et al. Growth hormone deficiency and replacement in elderly hypopituitary adults. KIMS Study Group and the KIMS International Board. Pharmacia and Upjohn International Metabolic Database. Clin Endocrinol (Oxf). 2000;53(3):281–289.
   PubMed Web of Science ®Google Scholar
• Jorgensen JOL, Juul A. THERAPY OF ENDOCRINE DISEASE: growth hormone replacement therapy in adults: 30 years of personal clinical experience. Eur J Endocrinol. 2018;179(1):R47–R56.
   PubMed Web of Science ®Google Scholar
• Toogood AA, Shalet SM. Growth hormone replacement therapy in the elderly with hypothalamic-pituitary disease: a dose-finding study. J Clin Endocrinol Metab. 1999;84(1):131–136.
   PubMed Web of Science ®Google Scholar
• Ricci Bitti S, Franco M, Albertelli M, et al. GH Replacement in the Elderly: is It Worth It? Front Endocrinol (Lausanne). 2021;12:680579.
   PubMed Web of Science ®Google Scholar
• Stochholm K, Johannsson G. Reviewing the safety of GH replacement therapy in adults. Growth Horm IGF Res. 2015;25(4):149–157.
   PubMed Web of Science ®Google Scholar
• Jorgensen JOL, Johannsson G, Barkan A. Should patients with adult GH deficiency receive GH replacement? Eur J Endocrinol. 2021;186(1):D1–D15.
   PubMed Web of Science ®Google Scholar
• Chanson P, Salenave S. Treatment of neurogenic diabetes insipidus. Annales d’endocrinologie. 2011;72(6):496–499.
   PubMed Web of Science ®Google Scholar
• Corona G, Giuliani C, Parenti G, et al. Moderate hyponatremia is associated with increased risk of mortality: evidence from a meta-analysis. PLoS One. 2013;8(12):e80451.
   PubMed Web of Science ®Google Scholar
• Arima H, Oiso Y, Juul KV, Nørgaard JP. Efficacy and safety of desmopressin orally disintegrating tablet in patients with central diabetes insipidus: results of a multicenter open-label dose-titration study. Endocr J. 2013;60(9):1085–1094.
   PubMed Web of Science ®Google Scholar
• Filippatos TD, Makri A, Elisaf MS, Liamis G. Hyponatremia in the elderly: challenges and solutions. Clin Interv Aging. 2017;12:1957–1965.
   PubMed Web of Science ®Google Scholar
• Behan LA, Sherlock M, Moyles P, et al. Abnormal plasma sodium concentrations in patients treated with desmopressin for cranial diabetes insipidus: results of a long-term retrospective study. Eur J Endocrinol. 2015;172(3):243–250.
   PubMed Web of Science ®Google Scholar